Brexpiprazole | List of Frontiers open access articles

Brief Research Report

Published on 07 Aug 2025

Effects of adjunctive brexpiprazole in patients with major depressive disorder and sleep disturbance: a post hoc analysis of three randomized trials

in Psychopharmacology

Ferhat Ardic
Zhen Zhang
Michael Hogan

Frontiers in Psychiatry

doi 10.3389/fpsyt.2025.1618176

4,009 views
2 citations

Original Research

Published on 15 Jan 2026

Brexpiprazole inhibits EMT and migration of colorectal cancer cells by downregulating the SREBP1/SNAI1 signaling pathway

in Molecular and Cellular Oncology

Xiaojie Liu
Jingyi He
Ao Ma
Wenjun Xia
Zhiyang Xia
Lu Liu
Zhuoze Wu
Wei Chen

Frontiers in Oncology

doi 10.3389/fonc.2025.1734678

752 views

Original Research

Published on 09 Oct 2024

Identification of high-affinity Monoamine oxidase B inhibitors for depression and Parkinson’s disease treatment: bioinformatic approach of drug repurposing

in Experimental Pharmacology and Drug Discovery

Moyad Shahwan
Pratibha Prasad
Dharmendra Kumar Yadav
Nojood Altwaijry
Mohd Shahnawaz Khan
Anas Shamsi

Frontiers in Pharmacology

doi 10.3389/fphar.2024.1422080

3,672 views
2 citations

Case Report

Published on 22 Jul 2022

Case report: Effectiveness of brexpiprazole and esketamine/ketamine combination: A novel therapeutic strategy in five cases of treatment-resistant depression

in Psychopharmacology

Lai Fong Chan
Luke Sy-Cherng Woon
Nuur Asyikin Mohd Shukor
Choon Leng Eu
Nurazah Ismail
Song Jie Chin
Nik Ruzyanei Nik Jaafar
Azlin Baharudin

Frontiers in Psychiatry

doi 10.3389/fpsyt.2022.890099

7,671 views
1 citation

Original Research

Published on 04 Dec 2023

Brexpiprazole in patients with schizophrenia with or without substance use disorder: an observational study

in Schizophrenia

Ginevra Lombardozzi
Giada Trovini
Emanuela Amici
Georgios D. Kotzalidis
Filippo Perrini
Valeria Giovanetti
Alessandro Di Giovanni
Sergio De Filippis

Frontiers in Psychiatry

doi 10.3389/fpsyt.2023.1321233

6,860 views
11 citations

Review

Published on 29 Nov 2022

Third-generation antipsychotics in patients with schizophrenia and non-responsivity or intolerance to clozapine regimen: What is the evidence?

in Psychopharmacology

Octavian Vasiliu

Frontiers in Psychiatry

doi 10.3389/fpsyt.2022.1069432

32,790 views
28 citations

Review

Published on 25 Jan 2022

Dopamine Receptor Partial Agonists: Do They Differ in Their Clinical Efficacy?

in Psychopharmacology

Pavel Mohr
Jirí Masopust
Miloslav Kopeček

Frontiers in Psychiatry

doi 10.3389/fpsyt.2021.781946

49,175 views
45 citations

Original Research

Published on 23 Jul 2024

Defining a clinically meaningful within-patient change threshold for the Cohen-Mansfield Agitation Inventory in Alzheimer’s dementia

in Dementia and Neurodegenerative Diseases

Juliette Meunier
Kristin Creel
Angély Loubert
Klaus Groes Larsen
Jyoti Aggarwal
Nanco Hefting
Dorothee Oberdhan

Frontiers in Neurology

doi 10.3389/fneur.2024.1379062

6,589 views
11 citations

Case Report

Published on 19 Mar 2024

Case report: Avoiding intolerance to antipsychotics through a personalized treatment approach based on pharmacogenetics

in Psychopharmacology

Liam Korošec Hudnik
Tanja Blagus
Sara Redenšek Trampuž
Vita Dolžan
Jurij Bon
Milica Pjevac

Frontiers in Psychiatry

doi 10.3389/fpsyt.2024.1363051

5,604 views
5 citations

Review

Published on 16 Feb 2023

The pharmacogenetics of the new-generation antipsychotics – A scoping review focused on patients with severe psychiatric disorders

in Psychopharmacology

Octavian Vasiliu

Frontiers in Psychiatry

doi 10.3389/fpsyt.2023.1124796

11,563 views
17 citations

Original Research

Published on 26 Mar 2025

Assessment of minimum clinically important difference in symptoms and functionality of Japanese patients with major depressive disorder following inadequate response to antidepressants: a post hoc analysis of the long-term study of brexpiprazole augmentation therapy in Japanese patients with major depressive disorder

in Mood Disorders

Hikaru Hori
Masako Shiosakai
Yoshiyuki Shibasaki
Kentaro Yamato
Yilong Zhang

Frontiers in Psychiatry

doi 10.3389/fpsyt.2025.1556470

3,341 views

Articles

Effects of adjunctive brexpiprazole in patients with major depressive disorder and sleep disturbance: a post hoc analysis of three randomized trials

Brexpiprazole inhibits EMT and migration of colorectal cancer cells by downregulating the SREBP1/SNAI1 signaling pathway

Identification of high-affinity Monoamine oxidase B inhibitors for depression and Parkinson’s disease treatment: bioinformatic approach of drug repurposing

Case report: Effectiveness of brexpiprazole and esketamine/ketamine combination: A novel therapeutic strategy in five cases of treatment-resistant depression

Brexpiprazole in patients with schizophrenia with or without substance use disorder: an observational study

Third-generation antipsychotics in patients with schizophrenia and non-responsivity or intolerance to clozapine regimen: What is the evidence?

Dopamine Receptor Partial Agonists: Do They Differ in Their Clinical Efficacy?

Defining a clinically meaningful within-patient change threshold for the Cohen-Mansfield Agitation Inventory in Alzheimer’s dementia

Case report: Avoiding intolerance to antipsychotics through a personalized treatment approach based on pharmacogenetics

The pharmacogenetics of the new-generation antipsychotics – A scoping review focused on patients with severe psychiatric disorders